RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
Complete the form below to unlock access to ALL audio articles.
Rainbow Coral Corp. opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector.
Transdermal patches are an increasingly popular drug delivery system that is being developed for everything from contraception to Parkinson's disease. Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes and offer major advantages such as improved bioavailability, more uniform plasma levels, longer duration of action, reduced side effects and improved therapy.
Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion by 2015 from a value of $21.5 billion just three years ago. RBCC expects that partnering with an emerging leader in the sector could help the company capture a big piece of that growth.
“Transdermal patches offer a non-invasive option for treating many diseases and disorders,” said RBCC CEO Patrick Brown. “The appeal is obvious. We’re in negotiations now with a patch developer we believe has high profit potential, and we’re optimistic that a deal can be struck soon.”
